{"protocolSection": {"identificationModule": {"nctId": "NCT00927758", "orgStudyIdInfo": {"id": "CP-Sandoz-2009-PilotFP"}, "organization": {"fullName": "Sandoz", "class": "INDUSTRY"}, "briefTitle": "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair", "officialTitle": "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-06"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-06-23", "studyFirstSubmitQcDate": "2009-06-24", "studyFirstPostDateStruct": {"date": "2009-06-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-04-22", "resultsFirstSubmitQcDate": "2014-08-29", "resultsFirstPostDateStruct": {"date": "2014-09-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-03-27", "lastUpdatePostDateStruct": {"date": "2017-03-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sandoz", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 105, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}, {"label": "Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}, {"label": "Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}, {"label": "Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}, {"label": "Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}, {"label": "Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg", "type": "ACTIVE_COMPARATOR", "description": "Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.\n\nThere were 14 days washout period between cycles.", "interventionNames": ["Drug: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg"]}], "interventions": [{"type": "DRUG", "name": "fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg", "description": "fluticasone propionate/salmeterol diskus", "armGroupLabels": ["Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg", "Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg", "Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg", "Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg", "Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg", "Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg"], "otherNames": ["Advair DISKUS"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)", "description": "Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.", "timeFrame": "Baseline to Day 7 of each treatment cycle (total duration about 8 - 10 weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* must be able to speak, read, and understand English\n* exhaled Nitrous Oxide levels must be greater than or equal to 60 ppb at screening and greater than or equal to 55 ppb at Visits 2, 9, and 16\n* must have history of at least 6 months of chronic, but stable asthma\n* except for the presence of asthma, subjects must be in general good health\n\nExclusion Criteria:\n\n* past or present history of experiencing allergic reaction to medications used in this study\n* subjects must not be receiving ongoing regular treatment with inhaled corticosteroids\n* subjects must not have ragweed allergy\n* subjects must have no recent history of respiratory infections for at least 1 month prior to screening and until the end of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32610-0486", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "CompleWare", "city": "Iowa City", "state": "Iowa", "zip": "52244", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Actual screened patients was 105. However, 22 eligible patients were randomized.", "groups": [{"id": "FG000", "title": "Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}, {"id": "FG001", "title": "Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}, {"id": "FG002", "title": "Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}, {"id": "FG003", "title": "Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}, {"id": "FG004", "title": "Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}, {"id": "FG005", "title": "Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg", "description": "Treatment cycle 1: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for\n\n7 days.\n\nTreatement Cycle 2 : Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for\n\n7 days.\n\nTreatment Cycle 3: Patient randomized to Fluticasone\n\nPropionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for\n\n7 days.\n\nThere were 14 days washout period between cycles."}], "periods": [{"title": "Treatment Cycle 1 (Day 1 - Day 7)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "\"Started \" indicates randomized as well as safety set.", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "Intent to Treat (ITT)", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}]}, {"title": "Treatment Cycle 2 (Day 1 - Day 7)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "Per Protocol Population (PP)", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Did not meet eNO criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}]}, {"title": "Treatment Cycle 3 (Day 1 - Day 7)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Randomized Patients", "description": "Baseline measured for all randomized (safety set) patients."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "22"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.86", "spread": "10.40"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)", "description": "Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.", "populationDescription": "The per-protocol (PP) population was all subjects who completed the study with no major variances that would impair the analysis of the data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage change in eNO", "timeFrame": "Baseline to Day 7 of each treatment cycle (total duration about 8 - 10 weeks)", "groups": [{"id": "OG000", "title": "Flu/Sal- 100mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days."}, {"id": "OG001", "title": "Flu/Sal- 250mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days."}, {"id": "OG002", "title": "Flu/Sal- 500mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.65", "spread": "18.74"}, {"groupId": "OG001", "value": "45.31", "spread": "16.46"}, {"groupId": "OG002", "value": "54.58", "spread": "12.55"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "description": "Safety set includes all subjects who received at least one dose of drug.", "eventGroups": [{"id": "EG000", "title": "Flu/Sal- 100mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 3, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Flu/Sal- 250mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 1, "otherNumAtRisk": 19}, {"id": "EG002", "title": "Flu/Sal- 500mcg/50mcg", "description": "All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 17, "otherNumAffected": 5, "otherNumAtRisk": 17}], "seriousEvents": [{"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}]}], "otherEvents": [{"term": "Viral Upper respiratory infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Upper Respiratory infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 17}]}, {"term": "Worsening Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 17}]}, {"term": "Dilated, Dry Eyes", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Sandoz's agreements with its investigators may vary. However, Sandoz does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Sandoz", "email": "yaping.zhu@sandoz.com", "phone": "609-627-8889"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M12507", "name": "Nitric Oxide", "relevance": "LOW"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Fabry Disease", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}